Climb Bio, Inc. (NASDAQ:CLYM – Free Report) – Investment analysts at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for Climb Bio in a report released on Monday, December 2nd. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($1.57) for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Climb Bio’s FY2025 earnings at ($0.65) EPS and FY2026 earnings at ($0.82) EPS.
Separately, Leerink Partners assumed coverage on Climb Bio in a report on Monday. They issued an “outperform” rating and a $10.00 price target for the company.
Climb Bio Price Performance
Climb Bio stock opened at $3.09 on Wednesday. Climb Bio has a one year low of $2.35 and a one year high of $11.55. The firm has a market capitalization of $207.71 million, a PE ratio of -1.47 and a beta of -0.40.
Climb Bio Company Profile
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Featured Articles
- Five stocks we like better than Climb Bio
- EV Stocks and How to Profit from Them
- Tesla Poised to Hit Record Highs This Holiday Season
- What Is WallStreetBets and What Stocks Are They Targeting?
- The Salesforce Rally is Just Getting Started: Here’s Why
- Conference Calls and Individual Investors
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
